CD8A and non-small cell lung carcinoma: Consistent with these findings, Topper et al. recently found that DNMTi and HDACi combination therapy induced potent immune responses, including an enhanced interferon gamma signature, CD8 T cell infiltration, and PD-L1 expression in a murine NSCLC model, supporting the potential benefit of checkpoint inhibitor therapy following epigenetic therapies53.